Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal
Get Alerts TEVA Hot Sheet
Price: $13.25 +1.84%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Join SI Premium – FREE
Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).
In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.
Teva and Mylan are both trading at or near session lows on Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount Global (PARA) and Skydance are closer to a merger - CNBC
- Meta earnings, IBM to acquire HashiCorp, U.S. GDP ahead - what's moving markets
- InVitae (NVTA) Enters into Agreement with Labcorp (LH) for Sale of Business
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and AcquisitionsRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!